Thalia TherapeuticsLSE:THAT Pretax Margin % is -17,375.00% as of Dec. 2025. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Thalia Therapeutics ranks worse than 94.39% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Thalia Therapeutics Pretax Margin % Related Terms
Thalia Therapeutics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Thalia Therapeutics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:THAT vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Thalia Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thalia Therapeutics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Thalia Therapeutics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Thalia Therapeutics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thalia Therapeutics (LSE:THAT) has a Pretax Margin % of -17,375.00% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Thalia Therapeutics and its competitors. According to the industry distribution chart, Thalia Therapeutics ranks #892 out of 945 companies in the Biotechnology industry, placing it in the top 94.4%.
Is Thalia Therapeutics' Pretax Margin % too high?
Thalia Therapeutics' current Pretax Margin % is -17,375.00%. Based on the distribution chart, Thalia Therapeutics ranks #892 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Thalia Therapeutics' Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thalia Therapeutics ranks #892 out of 945 companies for Pretax Margin %. This places Thalia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Thalia Therapeutics and its competitors. Thalia Therapeutics's current Pretax Margin % is -17,375.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thalia Therapeutics stock overvalued right now?
Thalia Therapeutics (LSE:THAT) has a current Pretax Margin % of -17,375.00%. The current Pretax Margin % is -17,375.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Thalia Therapeutics (LSE:THAT), the current Pretax Margin % is -17,375.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Thalia Therapeutics PLC is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. Its pipeline includes a long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein(a) [Lp(a)], which are established risk factors for cardiovascular disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:THAT has been successfully added to your 